Assess whether pediatric studies are necessary or waivable (25038d)

Situation

After a competitor label that just got a narrower indication, 505(b)(2) literature-to-product bridge table is what labeling negotiator can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with Pediatric studies are necessary versus Waivable on this CMC and Development Pathways file.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Pediatric studies are necessary / Waivable using 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication.

Hypotheses to test

• A competitor label that just got a narrower indication is noise around an already-controlled CMC and Development Pathways process in a 505(b)(2) program relying on literature plus a bridging study, given 505(b)(2) literature-to-product bridge table.
• A competitor label that just got a narrower indication is the event in 505(b)(2) literature-to-product bridge table that forces Pediatric studies are necessary for labeling negotiator under Pharma & Life Sciences.
• 505(b)(2) literature-to-product bridge table shows a one-file miss after a competitor label that just got a narrower indication, not a CMC and Development Pathways program failure.
• 505(b)(2) literature-to-product bridge table cannot decide pediatric studies are necessary yet after a competitor label that just got a narrower indication; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a competitor label that just got a narrower indication and write the one fact that would move pediatric studies are necessary for labeling negotiator.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.